Ipsen's Bylvay has failed to meet its primary endpoint in the Phase 3 BOLD trial for biliary atresia, a rare pediatric liver disease, undermining hopes for a major label expansion in this high‑need population.
The BOLD trial, involving 254 patients across 19 countries, aimed to show improved native liver survival versus placebo at 104 weeks, but Bylvay did not demonstrate this benefit despite maintaining its established safety profile.
The setback compounds pressure on Ipsen’s Albireo portfolio, which was acquired for $952 million and already saw the pruning of other pipeline assets amid slower-than-expected momentum in rare‑liver indications.
Financially, Bylvay remains a key revenue driver with more than €180 million in 2025 sales, but the biliary‑atresia failure raises questions about the long‑term growth potential of the Albireo platform and could prompt strategic reassessment by Ipsen.
Sources:
Ipsen's Bylvay Fails Phase 3 BOLD Trial In Rare Pediatric Liver Disease
Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease
Ipsen : prendre ses profits sur les turbo calls (+58%)
Ipsen Says Phase 3 Trial of Bylvay in Biliary Atresia Misses Primary Endpoint
Ipsen fait le point sur l'essai de Phase III BOLD dans
Ipsen to Acquire Albireo - Growth in Rare Disease
Ipsen scuttles liver disease candidates from $952M Albireo ...
U.K. MHRA grants marketing authorisation for Ipsen's ...
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
Bylvay (odevixibat) for the Treatment of Pruritus, USA
Ipsen to Resubmit Orphan Designation for Bylvay in Alagille Syndrome
Bylvay eases itch, signs of liver damage in Alagille, trial data show